Chargement en cours...
Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance
We examined an immediate, but short-lived, response to crizotinib, a drug with a new indication for ROS1 rearranged non-small cell lung cancer (NSCLC) in a middle-aged non-smoker. The patient presented with metastatic NSCLC and extensive disease in multiple organs. He was treated with crizotinib 250...
Enregistré dans:
| Publié dans: | BMJ Case Rep |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5093785/ https://ncbi.nlm.nih.gov/pubmed/27797842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2016-217322 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|